Docetaxel is the first-line chemotherapy and the only approved chemotherapy for men with metastatic castrate resistant prostate cancer (CRPC). We all know that Docetaxel will stop working, so what do you do when this happens? […]
At Columbia University, New York City, Dr. Aaron Katz, in an online publication of Integrative Cancer Therapies reported positive effects on both androgen dependent (AD) and androgen independent (AI) prostate cancer of Modified Citrus Pectin (MCP) on both human and mouse prostate cancer cell lines (in the petrie dish). Dr. Kata, the lead researcher, reported [...]
In June of 2009 a team at UCSF Department of Urology announced a new prostate cancer risk assessment test that they claim can provide men and their doctors a better way of gauging long-term risks and pinpointing high risk cases of prostate cancer. The test, as indicated by the researchers, proved accurate in predicting bone [...]
There remain for many people questions about Provenge. The most common question I hear is about the financial cost of the treatment for what has been described as “only 4 months of life extension for $93,000, is it worth it?” Well, the answer is a clear yes! […]
President Barack Obama has nominated Harold E. Varmus, M.D., the Nobel Prize-winning scientist for studies showing how certain normal genes could cause cancer when they went awry; to serve as the 14th director of the National Cancer Institute (NCI). Dr. Varmus served as director of the National Institutes of Health in the 1990s, a period [...]